The Quiet Revolution: Seegnal’s AI Tackles Hospital Alert Fatigue

CALGARY, AB – June 25, 2026 – In the cacophony of a modern hospital, one of the most persistent and perilous sounds is the digital beep of a clinical alert. For decades, these warnings have been a double-edged sword: designed to prevent harm but so numerous and often irrelevant that they breed a dangerous habit of being ignored. This phenomenon, known as “alert fatigue,” is a critical weak point in patient safety. Now, a Calgary-based health tech firm is demonstrating how a more intelligent approach can silence the noise and amplify the signal.

Seegnal Inc. announced today it will deploy its AI-driven medication safety platform across Nazareth Hospital EMMS, a major trauma and teaching center in northern Israel. The five-year agreement marks another significant foothold for Seegnal in the Israeli healthcare system, where its technology is already used by approximately 15,000 clinicians. But the real story isn't just another software deal; it's a validation of a fundamental shift in how technology can and should support clinical judgment.

At the heart of the issue are adverse drug events (ADEs), which the World Health Organization identifies as a leading cause of preventable patient harm globally. Traditional clinical decision support (CDS) systems, often built into electronic health records (EHRs), attempt to prevent ADEs with automated checks, most commonly for drug-to-drug interactions. The result is a deluge of warnings, with studies showing clinicians override more than 90% of them. Seegnal’s approach is to replace this broad-spectrum, low-accuracy model with a patient-specific, high-precision one.

The Precision Prescription: A New Standard of Care

What sets Seegnal's SaaS platform apart is its ability to synthesize a comprehensive, real-time portrait of the individual patient. Instead of simply checking one drug against another, its decision engine integrates a wide array of patient-specific data points: current medications, laboratory results, kidney function, diagnoses, age, allergies, and even genetic information. This context-aware analysis allows the system to differentiate between a theoretical risk and a clear and present danger for a specific person.

The results, validated in peer-reviewed studies, are striking. A 2021 study at Boston’s prestigious Brigham & Women’s Hospital compared Seegnal to the conventional CDS embedded in Epic, one of the world's most widely used EHR systems. The findings were a powerful indictment of the status quo. Seegnal generated 94% fewer inpatient alerts than the incumbent system. More importantly, it achieved 99% specificity—meaning its alerts were almost always clinically relevant—compared to just 0.3% for the traditional system. This represents not an incremental improvement, but a paradigm shift in accuracy.

This isn't about replacing doctors with algorithms. Seegnal’s platform operates on a “human-in-the-loop” philosophy, where AI serves to augment, not automate, clinical judgment. By filtering out the noise, it empowers physicians and nurses to focus their attention on the handful of alerts that truly matter, providing explainable, clinically grounded recommendations and alternative medication suggestions. It’s a move from a system that shouts warnings to one that offers a trusted consultation.

From Regional Hub to Global Ambition

The agreement with Nazareth Hospital solidifies Seegnal’s position as a key player in Israel's vibrant health-tech ecosystem, a country that has effectively become a real-world laboratory for the company’s technology. The Israeli Ministry of Health has already adopted Seegnal’s patient-specific standard for its governmental hospitals, signaling strong institutional buy-in.

“Nazareth Hospital has stood at the heart of healthcare in the Galilee for more than 160 years, and we are honored to equip its clinicians with the same patient-specific medication safety standard now used by approximately 15,000 clinicians across Israeli hospitals and HMOs,” said Elad Bibi-Aviv, Chief Executive Officer of Seegnal.

This deep penetration in a sophisticated healthcare market provides a powerful springboard for the company's global ambitions. Seegnal is actively marketing its platform in the United Kingdom, the United Arab Emirates, and Poland. Critically, it has also initiated its first U.S. pilot program with a long-term care provider, a sector where complex medication regimens and polypharmacy make residents particularly vulnerable to ADEs.

The strategic timing is clear. The global clinical decision support market was valued at over $6.3 billion in 2025 and is projected to soar past $15 billion by 2033. Seegnal is positioning itself not as just another vendor, but as the provider of a new, more effective standard for a market hungry for solutions that deliver both clinical and economic value.

Modernizing a Legacy: Nazareth Hospital's Leap Forward

For Nazareth Hospital, the adoption of Seegnal’s platform is a significant step in its own evolution. Founded in 1861, the institution is a cornerstone of the Galilee community, serving as the main trauma center for a diverse population of approximately 570,000 people. As a teaching hospital affiliated with Bar-Ilan University, it is also responsible for training the next generation of medical professionals.

By integrating this advanced technology, the hospital is not only enhancing patient safety but also modernizing its clinical workflows for its 188 physicians and 236 nurses. The implementation demonstrates a commitment to blending its long heritage of community care with the cutting edge of medical innovation. For a teaching hospital, exposing trainees to such a precise decision-support tool provides an invaluable education in personalized medicine and responsible prescribing from the outset of their careers.

“Bringing Seegnal to a leading regional trauma center and teaching hospital is a meaningful step in our continued expansion across the Israeli healthcare system, and reflects our focus on delivering clinical and economic value at the point of care,” Bibi-Aviv added.

The Tangible Impact on Patient Health and Costs

Beyond the technological elegance and market strategy, the ultimate measure of any health innovation is its impact on human lives. Here again, the data is compelling. A large-scale controlled trial at Leumit Health Services, an Israeli HMO, linked Seegnal’s use to tangible clinical benefits. The study found a 5.6% reduction in hospitalizations among higher-risk patients and a 1.5% decrease in total medications dispensed, suggesting more optimized and efficient prescribing. Furthermore, physicians acted on the system’s insights, resolving 42% of the severe drug-safety risks it identified.

These numbers translate into profound real-world consequences: fewer hospital stays, reduced risk of harm from medication errors, and significant downstream cost savings for the healthcare system. By preventing even a fraction of adverse drug events, the platform pays for itself while improving the quality of patient care. The Nazareth Hospital deployment is the latest chapter in this story, promising to bring a higher standard of medication safety to one of Israel's most vital regional health providers.